Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors

NCT01562899 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01562899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01562899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Terminated
Start date
August 27, 2012
Completion date
April 1, 2015
Enrollment
77 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

braf mutated melanoma, metastatic pancreatic adenocarcinoma